Activated donor immune cells may prevent severe complication after allogeneic stem cell transplantation
Researchers have successfully completed a Phase I/II clinical trial for a new cell therapy, ATregs, designed to prevent graft-versus-host disease in stem cell transplant patients. The therapy uses activated regulatory T cells from healthy donors and can be prepared within 24 hours.
Why it matters
This breakthrough offers a potentially life-saving, scalable solution for patients undergoing stem cell transplants who are at high risk of fatal immune complications.
by Nadine Berger, Johannes Gutenberg University Mainz
edited by Lisa Lock , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Pixabay/CC0 Public Domain Researchers have successfully conducted the first clinical trial using activated regulatory T cells (ATregs, Actileucel)—derived from white blood cells of healthy blood donors. This novel cell therapy aims to prevent graft-versus-host disease (GvHD) following an allogeneic stem cell transplant. The Phase I/II study has yielded extremely encouraging results: ATregs can be produced within 24 hours and injected immediately afterward; administration is safe and well-tolerated by patients—a significant step toward a widely available cell therapy. The research is published in Transplantation and Cellular Therapy .
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in